Glaxo Touts Experimental Tykerb As Effective Breast-Cancer Treament
Reviewed By
Rating
Glaxo Touts Experimental Tykerb As Effective Breast-Cancer Treament
Our Review Summary
The story discusses the preliminary results of lapatinib (trade name Tykerb) and chemotherapy in HER-2 positive metastatic breast cancer patients. Patients who took lapatinib and the chemotherapy drug Xeloda remained stable (i.e. cancer did not spread further) nearly twice as long as patients who only had chemotherapy (8.5 months vs. 4.5 months). However, many drugs are effective in prolonging response in metastatic disease without impacting length of life. It would be good to get survival data to back up these claims, or at least provide data on quality of life to see whether the addition of lapatinib made a difference and how much. Additionally, the results of this trial have not been scrutinized in a peer-reviewed medical journal.
The story provides a powerful, but premature suggestion of equivalence between Herceptin and lapatinib. The suggeston is not evidenced based, as the two drugs have not been compared in a controlled trial. Potential cardiac side effects are a big issue for early-stage breast cancer patients, the group of women for whom this drug is already being tested as an alternative to Herceptin, so further research comparing the two drugs is needed.
This story relies solely on sources associated with the drug manufacturer. It also appears to rely heavily on information from a press release by the study sponsor, GlaxoSmithKline. Other oncology researchers are needed for perspective on the results of lapatinib as part of treatment for HER-2 positive cancer. The story mentions that lapatinib is still being tested in clinical trials and is not yet available for sale. The story says that “GlaxoSmithKline plans to submit the drug for regulatory approval in the U.S. and Europe by the end of this year,” and later mentions Glaxo’s “high hopes for Tykerb.” It would have been better to get some other perspectives about these prospects, other than comments from the company or company-sponsored researchers.
Criteria
Not Satisfactory
The story does not mentioned the proposed cost of lapatinib.
Satisfactory
The story provides early data from a trial of metastatic breast cancer patients. Cancers in these patients remained stable (i.e. it did not spread further in the body) nearly twice as long with the addition of lapatinib to chemotherapy (8.5 months vs. 4.5 months). There were fewer incidents of metastases to the brain in the women who took lapatinib and chemotherapy compared with chemotherapy alone (4 vs. 11 cases of cancer spreading to the brain). However, many drugs have been shown to effective in prolonging response in metastatic disease without impacting length of life so it would be good to get data on survival data to back up these claims or at least on quality of life to see whether it made a difference and how much.
Not Satisfactory
Cardiac side effects are reported as less serious than those seen in patients who were treated with Herceptin and chemotherapy. However, this comparison with Herceptin is not a fair one. In trials of Herceptin, the incidence of cardiac problems was about 4% at 3 years, so the reduction to 2.5% with lapatinib appears to be an improvement, but there is not enough information in this story on length of time patients took lapatinib and Herceptin to get those figures (and whether those are statistically different). Although long-term cardiac problems are less of an issue for metastatic patients, this side effect is potentially a big issue for early-stage breast cancer patients – a group of women for which this drug is already being tested as an alternative to Herceptin.
Not Satisfactory
The story does a good job describing the trial design and discussing the preliminary outcomes for further metastases and cardiac effects. However, the story provides a powerful but premature suggestion of equivalence between Herceptin and lapatinib and suggests that lapatinib may have superior benefits and reduced harms – despite the fact that the trial was in only 392 patients and it wasn’t a head-to head comparison with Herceptin.
Satisfactory
There is no evidence of disease mongering. The story accurately notes that only 20-25% of women would be eligible to take lapatinib, as they have the more aggressive form of breast cancer.
Not Satisfactory
The story relies solely on sources associated with GlaxoSmithKline. The lead author of the study is cited, however, the study was sponsored by this drug manufacturer. Additional oncology researchers are needed for perspective on the results of lapatinib in metastatic breast cancer patients.
Satisfactory
The story mentions Herceptin (generic name trastuzumab) and chemotherapy (here, Xeloda) as other treatments for HER-2 positive breast cancer.
Satisfactory
The story mentions that lapatinib is still being tested in clinical trails and is not yet available for sale. The story says that “GlaxoSmithKline plans to submit the drug for regulatory approval in the U.S. and Europe by the end of this year,” and later mentions Glaxo’s “high hopes for Tykerb.” It would have been better to get some other perspectives about these prospects, other than comments from the company or company-sponsored researchers.
Satisfactory
Tykerb (generic name lapatinib) is a new drug for the treatment of metastatic HER-2 positive breast cancer. The story discusses the mechanism by which this drug would inhibit tumor-cell growth.
Not Satisfactory
The story acknowledges that it took a quote from the principal investigator from a statement released by the drug company. The only other perspective in the story comes from a drug company staff scientist. There is no evidence of any independent reporting.
Total Score: 5 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.